Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Goldman

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.
Blood|February 29, 2012
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantationAristeidis Chaidos, Scott Patterson, Richard Szydlo, et al.
Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Blood|October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus, Brian Druker, Charles Sawyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Haematologica|April 21, 2009
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinibJamshid Sorouri Khorashad, Simon Wagner, Liat Greener, et al.
The Journal of Experimental Medicine|August 3, 2005
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersMark Cobbold, Naeem Khan, Batoul Pourgheysari, et al.
Blood|February 29, 2012
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantationAristeidis Chaidos, Scott Patterson, Richard Szydlo, et al.
Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Blood|October 13, 2007
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus, Brian Druker, Charles Sawyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Pageof 6